Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATYR PHARMA, INC.

(LIFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

aTyr Pharma : Jones Trading Adjusts Price Target for aTyr Pharma to $20 From $15, Maintains Buy Rating

09/13/2021 | 12:09pm EST


ę MT Newswires 2021
All news about ATYR PHARMA, INC.
01/13áaTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcem..
AQ
01/13aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Anno..
CI
01/06ATyr Pharma's ATYR1923 Granted Orphan Drug Designation by FDA to Treat Sarcoidosis
MT
01/06ATyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoid..
AQ
01/04ATyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
AQ
2021ATyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
AQ
2021Certain Restricted Stock Units of aTyr Pharma, Inc. are subject to a Lock-Up Agreement ..
CI
2021Certain Warrants of aTyr Pharma, Inc. are subject to a Lock-Up Agreement Ending on 16-D..
CI
2021Certain Common Stock of aTyr Pharma, Inc. are subject to a Lock-Up Agreement Ending on ..
CI
2021Certain Stock Options of aTyr Pharma, Inc. are subject to a Lock-Up Agreement Ending on..
CI
More news
Analyst Recommendations on ATYR PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 2,52 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,37x
Yield 2021 -
Capitalization 165 M 165 M -
Capi. / Sales 2021 65,5x
Capi. / Sales 2022 39,1x
Nbr of Employees 42
Free-Float 97,6%
Chart ATYR PHARMA, INC.
Duration : Period :
aTyr Pharma, Inc. Technical Analysis Chart | LIFE | US0021202025 | MarketScreener
Technical analysis trends ATYR PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 6,05 $
Average target price 18,50 $
Spread / Average Target 206%
EPS Revisions
Managers and Directors
Sanjay S. Shukla President, Chief Executive Officer & Director
Jill M. Broadfoot Chief Financial Officer
John K. Clarke Chairman
Leslie Nangle Vice President-Research
Paul R. Schimmel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ATYR PHARMA, INC.-19.01%168
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
ICON PUBLIC LIMITED COMPANY-17.32%20 842